Navigation Links
Duska Therapeutics Applies for Phase 3 Special Protocol Assessment
Date:11/20/2008

ous injection, is an investigational drug for the acute termination of PSVT. The bradycardic effect of ATP, in particular its blockade of atrio-ventricular (AV) nodal conduction, has been shown in multiple published clinical studies to safely and effectively terminate re-entrant PSVT involving the AV node. Injectable formulations of ATP, similar to ATPace, have been approved and marketed in Europe as pharmaceuticals for over 50 years as safe and efficacious treatments for PSVT.

Currently, adenosine is the only approved treatment for PSVT in the United States. Duska believes that the initial dose of ATPace will be significantly more efficacious than the initial labeled dose of adenosine in terminating PSVT. While both ATP and adenosine inhibit AV nodal conduction, ATP is believed to have dual inhibitory action, one mediated by adenosine, the product of its ATP's rapid enzymatic degradation, and the other a triggered vagal reflex. Vagal maneuvers, such as Valsalva maneuvers, aimed at enhancing vagal tone to the heart, and thereby suppressing atrio-ventricular nodal conduction, have been clinically used to terminate tachycardia in certain cases.

"The request for a SPA represents a significant milestone in the development of ATPace," stated James S. Kuo, MD, MBA, Duska's chief executive officer. "We believe that the Phase 3 clinical trial with ATPace should demonstrate the safety and efficacy of our drug in PSVT," he added.

About Duska (http://www.duskatherapeutics.com):

Duska is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging pharmacology of adenosine triphosphate (ATP) and nitric oxide (NO). These two molecules play critical roles in cellular metabolism and signal transduction, the manipulation of which constitute novel therapeutic modalities for the treatment of major cardiova
'/>"/>

SOURCE Duska Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Duska Therapeutics Licenses Portfolio of Heart Failure Drugs From Duke and Johns Hopkins
2. Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease
3. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
4. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
5. InteRNA Technologies and VU University Medical Center to Develop microRNA-Based Diagnostics and Therapeutics for Cancer
6. Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)
7. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
8. Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting
9. In Vivo Data on Taligen Therapeutics Pipeline Candidates Presented at the XXII International Complement Workshop
10. BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
11. Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 According to ... "Endoscopy Devices Market (Endoscopes, Endoscopic Operative Devices, and Visualization ... and Forecast, 2013-2019" the global endoscopy devices market was ... expected to grow at a CAGR of 6.8% from ... USD 36.9 billion in 2019. Browse the ...
(Date:7/11/2014)... Show organisers report ... Expo 2014 were a brand new audience ... London , plus a 10% increase ...      (Logo: http://photos.prnewswire.com/prnh/20130723/629764-a) ...      (Photo: http://photos.prnewswire.com/prnh/20140711/696892-b ) ...
(Date:7/10/2014)... , 11. Juli 2014 /PRNewswire/ ... Kameras für die molekulare Bildgebung, einschließlich ... heute die CE-Zulassung für sein Navigator ... kann Dilon das Produkt jetzt europaweit ... den Großteil der europäischen Länder ausgedehnt ...
Breaking Medicine Technology:Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2
... Inovio Pharmaceuticals, Inc. (NYSE Amex: INO ... preventive vaccines against cancers and infectious diseases, announced today ... in its Phase I clinical study of VGX-3400X, a ... influenza delivered using intramuscular (IM) electroporation. These results were ...
... Vapotherm, a privately held manufacturer of respiratory care devices ... received approval from the Medical Device Bureau of Health Canada ... later this year in the Canadian hospital market. The device ... "We are pleased to receive our license in ...
Cached Medicine Technology:Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I 2Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I 3Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I 4Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I 5Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I 6Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I 7Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I 8Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I 9Vapotherm Announces Approval in Canada for New High Flow Device Designed for Heliox 2
(Date:7/12/2014)... July 12, 2014 Ladies, it doesn't matter ... there. Those who are looking for an affordable gown can ... special occasion dresses) to get their dream items. Recently, the ... tea length gowns . Along with that, it is also ... enjoy the special offer; the deadline of this promotion is ...
(Date:7/11/2014)... July 12, 2014 According to ... total market is expected to register a CAGR ... , Browse 71 market data tables and 76 ... on "C4ISR Market"., http://www.marketsandmarkets.com/Market-Reports/c4isr-market-1315.html , Early ... http://www.marketsandmarkets.com/requestCustomization.asp?id=1315 , The report provides market ...
(Date:7/11/2014)... FRIDAY, July 11, 2014 (HealthDay News) -- Reducing the ... incidence of Lyme disease and other tick-borne infections ... that deer populations can be manipulated to reduce human ... of contracting Lyme disease," the researchers wrote. White-tailed ... which transmit Lyme disease to people. The study ...
(Date:7/11/2014)... UK (PRWEB) July 11, 2014 Microbiology ... of the in-vitro diagnostics industry, which is expected to ... ten years. The sector owes its growth to the ... to people’s health worldwide and a major factor leading ... technologies, threat of bio-terrorism, and a broader availability of ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Datalogic brings ... in improving sanitation hospital wide. With their new ... spread of disease, like the devastating MRSA, which claimed ... Gryphon GD4400-HC 2D and the Gryphon GM4400-HC ... barcodes and can even read barcodes off of troublesome ...
Breaking Medicine News(10 mins):Health News:Worldwide Brides-to-be: It Is Time To Show Your Beauty By Wearing A Trendy Summer Short Wedding Dress From Discount-Dress.com 2Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 2Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 3Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 4Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 2Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 3Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 2Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 3
... earthbound "angels" who have,brightened the lives of Michigan children ... The Caring for Children Angel Awards recognize good ... awards have been,sponsored annually by the Michigan Blues since ... a Friday, Nov. 9 reception and awards,program at the ...
... to remove,some fat (cellulite) and also tighten your skin ... Plastic Surgery and Laser Center in Farmington Hills,offers a ... goals -- without surgery. What,s more they can ... Farmington Hills plastic surgeon and,owner of the Center, said ...
... (NMA) announced the appointment of Byron Sogie-Thomas, M.S., ... Policy, Mr. Sogie-Thomas,will be responsible for advising the ... current policy issues. He will also assume overall,responsibility ... federal law,regulation, and policy. "Byron,s knowledge of ...
... Pharmacists Association (NCPA) is pleased today to announce ... public affairs., "We,re pleased to have such ... team," said Bruce Roberts, RPh, NCPA Executive Vice,President ... and,Administration experience will undoubtedly increase our organization,s,volume as ...
... for Hospital Quality,Improvement, BALTIMORE, Oct. 11 ... the mid-Atlantic region were,recently honored with a ... America. CareFirst BlueCross BlueShield (CareFirst) received,the 2007 ... 100,000 Lives and,Beyond Collaborative. CareFirst and the ...
... by diabetes to enter global,contest supporting children in developing nations and ... ... 11 "American Idol" finalist and,rising Hickory Records recording artist Elliott ... the Inspired by Diabetes global,campaign to support the care of children ...
Cached Medicine News:Health News:Blue Cross Blue Shield of Michigan Salutes Six 'Angels' 2Health News:Blue Cross Blue Shield of Michigan Salutes Six 'Angels' 3Health News:Prominent Farmington Plastic Surgeon Uses Two New Non-Surgical Procedures to Tighten Skin and Remove Fat 2Health News:National Medical Association Selects New Director of Health Policy 2Health News:Lisa Camooso Miller Joins National Community Pharmacists as Vice President of Public Affairs 2Health News:National Award Recognizes Delmarva Foundation and CareFirst BlueCross BlueShield Quality Improvement Efforts 2Health News:'American Idol' Finalist and Hickory Records Artist Elliott Yamin to Serve as a Global Ambassador for Inspired by Diabetes Campaign to Help Children with Diabetes 2Health News:'American Idol' Finalist and Hickory Records Artist Elliott Yamin to Serve as a Global Ambassador for Inspired by Diabetes Campaign to Help Children with Diabetes 3Health News:'American Idol' Finalist and Hickory Records Artist Elliott Yamin to Serve as a Global Ambassador for Inspired by Diabetes Campaign to Help Children with Diabetes 4Health News:'American Idol' Finalist and Hickory Records Artist Elliott Yamin to Serve as a Global Ambassador for Inspired by Diabetes Campaign to Help Children with Diabetes 5
... includes three major components: Blood pump, Cannulae, ... Driver. This system provides partial or total ... conventional therapy, is unable to maintain adequate ... support, blood flows from the natural heart ...
Datascope presents a unique new product for post-hemostasis puncture site management. Safeguard is the first product ever to combine a built-in inflatable bulb and a sterile dressing- providing adjus...
... catheter is inserted into the subclavian or ... vena cava. The Cool Line incorporates ... temperature-controlled saline flowing within a closed-loop design, ... circulation. The Cool Line combines two ...
... The Fortius catheter provides maximum ... to target temperature. The Fortius catheter ... design to provide the ultimate solution ... catheter is inserted percutaneously into the ...
Medicine Products: